New drug combination before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of new drugs given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it can shrink tumors and improve outcomes for patients whose cancer has certain markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach or gastroesophageal junction cancer that has not spread to distant organs and can be removed with surgery.
- You have not had any prior chemotherapy, radiation, or immunotherapy for this cancer.
- Your tumor tests positive for HER2 (a protein that helps cancer grow) and also has at least one of these markers: PD-L1 CPS ≥1, EBV, or dMMR/MSI-H.
- You are in generally good health (ECOG score 0-1) and have adequate organ function.
- You are not pregnant or breastfeeding, and you agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new investigational drugs (SHR-A1811 and SHR-A1701) given before surgery for stomach cancer that is HER2-positive and may respond to immunotherapy. The goal is to see if these drugs can shrink the tumor or improve outcomes when combined with surgery.
This trial tests giving a combination of immunotherapy, a growth factor to boost white blood cells, and chemotherapy before surgery for stomach cancer. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This study tests a combination of an existing targeted drug (trastuzumab) and a new experimental drug (retlirafusp alfa) for advanced stomach cancer that has a specific marker (HER2) and did not respond to initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.